Diego Erasun Mora, Ana Vázquez Del Campo, Alazne DE Castro Momioto, Alberto Muñoz Solano, Jose Schneider
{"title":"Colposcopic Alterations Are More Frequent in Smokers and Appear at a Younger Age.","authors":"Diego Erasun Mora, Ana Vázquez Del Campo, Alazne DE Castro Momioto, Alberto Muñoz Solano, Jose Schneider","doi":"10.21873/invivo.13946","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Tobacco use is a recognized cofactor risk for cervical cancer induced by high-risk Human Papilloma Virus (HR-HPV). This study aimed to evaluate the specific influence of tobacco use on colposcopic examination results in women infected by HR-HPV.</p><p><strong>Patients and methods: </strong>HR-HPV-positive women undergoing a loop electrosurgical excision procedure (LLETZ) after colposcopic examination were considered for this study. A total of 819 patients from a regional screening program were included, of whom 320 were smokers and 499 non-smokers.</p><p><strong>Results: </strong>Smokers were significantly younger (41.1 <i>vs.</i> 43.8, <i>p</i><0.01), more frequently exhibited grade II colposcopic changes (63.9% <i>vs.</i> 53.3%, <i>p</i><0.05), had worse histopathological outcomes (CIN2+: 75.7% <i>vs.</i> 67.9%, <i>p</i><0.05; CIN3+: 51.4% <i>vs.</i> 44.0%, <i>p</i><0.05), and higher rates of affected surgical margins, with borderline significance (22.6% <i>vs.</i> 17.8%, <i>p</i>=0.055). While no significant differences in viral clearance were observed at six months, smokers showed a trend toward worse outcomes at two years (<i>p</i>=0.07).</p><p><strong>Conclusion: </strong>Smoking in any amount is associated with worse colposcopic and histopathological findings, and this occurs at younger ages.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1453-1457"},"PeriodicalIF":1.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12041987/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.13946","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: Tobacco use is a recognized cofactor risk for cervical cancer induced by high-risk Human Papilloma Virus (HR-HPV). This study aimed to evaluate the specific influence of tobacco use on colposcopic examination results in women infected by HR-HPV.
Patients and methods: HR-HPV-positive women undergoing a loop electrosurgical excision procedure (LLETZ) after colposcopic examination were considered for this study. A total of 819 patients from a regional screening program were included, of whom 320 were smokers and 499 non-smokers.
Results: Smokers were significantly younger (41.1 vs. 43.8, p<0.01), more frequently exhibited grade II colposcopic changes (63.9% vs. 53.3%, p<0.05), had worse histopathological outcomes (CIN2+: 75.7% vs. 67.9%, p<0.05; CIN3+: 51.4% vs. 44.0%, p<0.05), and higher rates of affected surgical margins, with borderline significance (22.6% vs. 17.8%, p=0.055). While no significant differences in viral clearance were observed at six months, smokers showed a trend toward worse outcomes at two years (p=0.07).
Conclusion: Smoking in any amount is associated with worse colposcopic and histopathological findings, and this occurs at younger ages.
期刊介绍:
IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management.
The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.